Physician profile
Daniel T Suzuki
NPI 1811025679
$862,234.99
in general payments reported to CMS, 2019-2025
28 companies · $215K in 2025
The $215K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142K · 2020: $40K · 2021: $64K · 2022: $111K · 2023: $102K · 2024: $188K · 2025: $215K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $363K · Consulting Fee: $63K · Travel and Lodging: $35K · Honoraria: $22K · Food and Beverage: $21K · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $363,315.45 |
| Consulting Fee | $62,603.00 |
| Travel and Lodging | $35,003.30 |
| Honoraria | $22,275.00 |
| Food and Beverage | $21,468.26 |
| Education | $121.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $281,661.27 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $187,206.02 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $185,517.80 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $118,062.56 | 2019-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $56,738.87 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $23,075.93 | 2019-2025 | Trintellix |
| Eisai INC. | $2,820.00 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,145.32 | 2021-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,267.60 | 2019-2024 | Abilify Asimtufii, Rexulti |
| Abbvie INC. | $621.60 | 2021-2025 | Vraylar |
| Janssen Scientific Affairs, LLC | $499.86 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $479.28 | 2019-2022 | |
| Lundbeck LLC | $479.22 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $348.22 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $251.46 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $197.00 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $186.22 | 2023-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $117.10 | 2019-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $109.38 | 2019-2025 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $98.91 | 2019-2024 | Jornay Pm |
| Almatica Pharma LLC | $90.92 | 2024-2025 | Loreev Xr |
| Corium, LLC | $75.74 | 2023-2025 | Azstarys |
| Neos Therapeutics, Lp | $43.14 | 2019 | |
| Neuronetics, INC. | $42.27 | 2023 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $36.76 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $32.15 | 2019 | |
| Indivior INC. | $17.94 | 2020 | |
| Alfasigma USA, INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Suzuki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.